AdvanCell-preview

Advancell-com

AdvanCell

Private

SydneyHealthcare & Life Scienceshttps://advancell.com.au

Last Round

Grant

Apr 14, 2025

Total Funding Raised

$146M

Momentum Score

75 /100

Company Overview

AdvanCell is a clinical-stage radiopharmaceutical company that develops targeted alpha therapies for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Hardware Sales, Revenue Share

AI Layer

Non-AI

Keywords

targeted alpha therapyTATradiopharmaceuticalsradiopharmaisotope productionLead-212alpha therapyisotope generatormetastatic prostate cancerclinical-stage company²¹²Pbradiochemistryoncology therapiesdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AdvanCell Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AdvanCell Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Apr 14, 2025
Series C	Feb 3, 2025
Grant	Jul 5, 2023
Series B	Aug 24, 2022
Grant	Dec 15, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Andrew Adamovich

Chief Executive Officer, Managing Director

Executive Team

Sam Lo Ricco

Interim CFO (SVP Finance)

Executive Team

Chris Horvath

Chief Commercial Officer Chief Operating Officer

Executive Team

AdvanCell Investors

Notable investors and investment history

Investor	Rounds
SymBiosis Capital Management	Series C
SV Health Investors	Series C
Medical Research Future Fund	Grant
Morningside Ventures	Series C
Abingworth	Series C
Sanofi Ventures	Series C
Morningside Group	Series C

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Feb 25, 2026
Presented novel TheraPb Phase 2 study design at ASCO GU Symposium 2026.
Feb 25, 2026
Announced Phase 2 study design for ADVC001 at ASCO GU Symposium.

View all signals

AdvanCell Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

AdvanCell Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AdvanCell's valuation, stock price, and market status.

Firmographic Details

HeadquartersSydney

Employee Range81

Year Founded2019

Last FundingApr 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.